Newsroom
Keep up with the latest
Featured
Scribe Therapeutics Highlights Data Underpinning its Comprehensive Strategy Targeting Key Lipid Drivers of ASCVD at American Heart Association (AHA) Scientific Sessions 2025
November 17, 2025
Scribe Therapeutics Highlights Data Underpinning its Comprehensive Strategy Targeting Key Lipid Drivers of ASCVD at American Heart Association (AHA) Scientific Sessions 2025
November 17, 2025
Epigenetic editors are a gentler form of gene editing
February 24, 2025
The Economist
Epigenetic editors are a gentler form of gene editing
February 24, 2025
Media Center
Media
Advancing CRISPR Cures Requires Cross-Sector Collaboration
June 13, 2025
Genetic Engineering & Biotechnology News
Read Now
Press Release
Advancing CRISPR Cures Requires Cross-Sector Collaboration
June 13, 2025
Genetic Engineering & Biotechnology News
Read Now
Media
U.S. Innovation, Strategy Needed to Counter China’s Rise in Biotech
May 29, 2025
The Wall Street Journal
Read Now
Press Release
U.S. Innovation, Strategy Needed to Counter China’s Rise in Biotech
May 29, 2025
The Wall Street Journal
Read Now
Media
Heart Disease Could Be a Goner When These New Drugs Arrive
May 23, 2025
Barron's
Read Now
Press Release
Heart Disease Could Be a Goner When These New Drugs Arrive
May 23, 2025
Barron's
Read Now
Press Release
Scribe Therapeutics Reports Positive Preclinical Data on its Novel CRISPR Technologies at the 2025 EAS Congress and ASGCT Annual Meeting
May 22, 2025
Read Now
Press Release
Scribe Therapeutics Reports Positive Preclinical Data on its Novel CRISPR Technologies at the 2025 EAS Congress and ASGCT Annual Meeting
May 22, 2025
Read Now
Media
DNA Island: Alameda is attracting biotechs amid an industrywide downturn
May 15, 2025
San Francisco Business Times
Read Now
Press Release
DNA Island: Alameda is attracting biotechs amid an industrywide downturn
May 15, 2025
San Francisco Business Times
Read Now
Press Release
Scribe Therapeutics to Highlight In Vivo CRISPR-based Genome Editing Data for Duchenne Muscular Dystrophy at ASGCT 2025, in Addition to Joint Presentation with Prevail Therapeutics, a part of Lilly’s Gene Therapy Division
May 5, 2025
Read Now
Press Release
Scribe Therapeutics to Highlight In Vivo CRISPR-based Genome Editing Data for Duchenne Muscular Dystrophy at ASGCT 2025, in Addition to Joint Presentation with Prevail Therapeutics, a part of Lilly’s Gene Therapy Division
May 5, 2025
Read Now
Blog